Comparative Pharmacology
Head-to-head clinical analysis: ERELZI versus HUMIRA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERELZI versus HUMIRA.
ERELZI vs HUMIRA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erelzi (etanercept-szzs) is a tumor necrosis factor (TNF) blocker. It is a dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) TNF receptor linked to the Fc portion of human IgG1. Erelzi binds specifically to TNF-alpha and blocks its interaction with cell surface TNF receptors, thereby reducing TNF-mediated inflammatory responses.
Tumor necrosis factor alpha (TNF-α) inhibitor; a recombinant human IgG1 monoclonal antibody that binds to soluble and membrane-bound TNF-α, preventing its interaction with p55 and p75 TNF receptors, thereby reducing inflammation and immune activation.
For plaque psoriasis: 100 mg subcutaneous injection once weekly, after initial loading dose of 200 mg at weeks 0, 1, 2, 3, and 4. For psoriatic arthritis: 100 mg subcutaneous injection once weekly.
Adult: 40 mg subcutaneously every other week. For ulcerative colitis: initial dose 160 mg on day 1, then 80 mg on day 15, then 40 mg every other week starting day 29.
None Documented
None Documented
Terminal elimination half-life: 13–16 days (mean 14.6 days) in adults with moderate-to-severe plaque psoriasis; clinical context: supports every-2-week subcutaneous dosing regimen.
Terminal elimination half-life is approximately 14 days (range 10–20 days) in adults, supporting a subcutaneous dosing interval of every 2 weeks. Longer half-life in older patients.
Renal: negligible (not significantly excreted unchanged); Biliary/Fecal: primary elimination pathway via proteolytic catabolism to amino acids; approximately 95% of dose recovered as small peptides/amino acids in feces.
Adalimumab is primarily eliminated via reticuloendothelial system degradation; no significant renal or biliary excretion. <1% excreted unchanged in urine.
Category C
Category C
TNF-alpha Inhibitor
TNF-alpha Inhibitor